Pacira BioSciences (NASDAQ:PCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Pacira BioSciences (NASDAQ:PCRX) had its price target upped by research analysts at Needham & Company LLC from $30.00 to $32.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 26.08% from the stock’s previous close.

Several other research analysts also recently commented on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.44.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $25.38 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock’s fifty day moving average is $23.06 and its two-hundred day moving average is $18.50. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a market capitalization of $1.17 billion, a PE ratio of -12.50 and a beta of 0.80.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently bought and sold shares of the stock. State of Wyoming increased its holdings in shares of Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company’s stock valued at $124,000 after acquiring an additional 487 shares during the period. PNC Financial Services Group Inc. grew its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Pacira BioSciences by 3.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock worth $491,000 after purchasing an additional 794 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after buying an additional 918 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after buying an additional 1,208 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.